TLR2 and myelodysplastic syndrome: Individuals diagnosed with MDS commonly exhibit increased innate immune signaling, typified by elevated TLR2 and TLR4 expression levels observed in CD34+ HSPCs from 15 patients who experienced hypomethylating agent (HMA) therapy failure, as investigated by Paracatu et al.